Zydaclin Warnings and Precautions


Keep out of reach of children. Not for human use.


During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

The use of ZydaClin™ Oral Drops occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of ZydaClin™ Oral Drops should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see CONTRAINDICATIONS). Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high dose therapy.

Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, ZydaClin™ Oral Drops should be used with caution in animals receiving such agents.

Safety in gestating bitches and queens or breeding male dogs and cats has not been established.

Zydaclin Overview

Overall Rating
Medication Type
Approval Date
Jul 25, 2013
DEA Schedule
Not Classified

Get The Daily Newsletter